HC Wainwright Issues Pessimistic Forecast for NAGE Earnings

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Analysts at HC Wainwright dropped their Q2 2026 EPS estimates for shares of Niagen Bioscience in a research report issued on Monday, May 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.02 per share for the quarter, down from their prior estimate of $0.04. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Niagen Bioscience’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Niagen Bioscience’s Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.10 EPS, FY2026 earnings at $0.28 EPS, Q1 2027 earnings at $0.06 EPS, Q2 2027 earnings at $0.08 EPS, Q4 2027 earnings at $0.12 EPS and FY2027 earnings at $0.36 EPS.

Other analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a report on Tuesday, April 21st. Finally, Canaccord Genuity Group decreased their price target on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Niagen Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $14.67.

Niagen Bioscience Trading Down 4.6%

Niagen Bioscience stock opened at $3.98 on Tuesday. The firm’s 50 day simple moving average is $4.69 and its 200 day simple moving average is $5.77. The firm has a market capitalization of $316.97 million, a PE ratio of 18.95 and a beta of 2.17. Niagen Bioscience has a 1-year low of $3.93 and a 1-year high of $14.69.

Niagen Bioscience (NASDAQ:NAGE) last posted its earnings results on Wednesday, May 6th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $31.47 million for the quarter. Niagen Bioscience had a net margin of 14.29% and a return on equity of 22.68%.

Hedge Funds Weigh In On Niagen Bioscience

A number of institutional investors have recently made changes to their positions in the stock. Hillsdale Investment Management Inc. purchased a new stake in shares of Niagen Bioscience in the 3rd quarter valued at $2,988,000. JPMorgan Chase & Co. purchased a new stake in shares of Niagen Bioscience in the 3rd quarter valued at $3,678,000. Gamco Investors INC. ET AL purchased a new stake in shares of Niagen Bioscience in the 3rd quarter valued at $1,170,000. Navellier & Associates Inc. purchased a new stake in shares of Niagen Bioscience in the 3rd quarter valued at $1,768,000. Finally, Gabelli Funds LLC purchased a new stake in shares of Niagen Bioscience in the 3rd quarter valued at $1,749,000. Institutional investors own 15.41% of the company’s stock.

Key Niagen Bioscience News

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: HC Wainwright raised its Q4 2027 EPS estimate to $0.12 from $0.11, suggesting improved longer-term earnings potential while maintaining a Buy rating and $11 target.
• Neutral Sentiment: The analyst also highlighted updated estimates across 2026–2027, including FY2026 EPS of $0.28 and FY2027 EPS of $0.36, indicating continued coverage but no major change to the overall investment thesis.
• Negative Sentiment: HC Wainwright cut its near-term EPS outlook for Niagen Bioscience, lowering Q2 2026 to $0.02 from $0.04, Q3 2026 to $0.08 from $0.10, Q4 2026 to $0.10 from $0.12, Q1 2027 to $0.06 from $0.07, Q2 2027 to $0.08 from $0.09, and FY2026/FY2027 estimates to $0.28 and $0.36 from $0.33 and $0.37, respectively.
• Negative Sentiment: HC Wainwright also lowered its price target from $12 to $11, which can be read as a modestly softer valuation view despite the bullish rating.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.